Eculizumab
Eculizumab is a monoclonal antibody that is used in the treatment of various autoimmune diseases. It is marketed under the trade name Soliris by Alexion Pharmaceuticals.
Mechanism of Action
Eculizumab works by inhibiting the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism. It does this by binding to the complement protein C5, preventing it from splitting into C5a and C5b. This inhibits the inflammatory response and the formation of the membrane attack complex, which is responsible for cell lysis.
Uses
Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease of the blood characterized by hemolysis, thrombosis, and peripheral cytopenia. It is also used in the treatment of atypical hemolytic uremic syndrome (aHUS), another rare disease that causes abnormal blood clots to form in small blood vessels in the kidneys. More recently, it has been approved for use in treating neuromyelitis optica spectrum disorder (NMOSD), a rare neurological condition.
Side Effects
Common side effects of eculizumab include headache, nausea, anemia, and fatigue. Serious side effects can include life-threatening infections, such as meningococcal infections, due to the drug's effect on the immune system.
History
Eculizumab was first approved by the Food and Drug Administration (FDA) in 2007 for the treatment of PNH. It was the first drug approved for this condition. In 2011, it was approved for the treatment of aHUS. In 2019, it was approved for the treatment of NMOSD.
See Also
- Monoclonal antibodies
- Autoimmune diseases
- Paroxysmal nocturnal hemoglobinuria
- Atypical hemolytic uremic syndrome
- Neuromyelitis optica spectrum disorder
Hypersensitivity and autoimmune diseases (279.5–6) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Monoclonal antibodies | ||||||||
---|---|---|---|---|---|---|---|---|
This Monoclonal antibodies related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD